Disease Landscape and Forecast Insights

Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…

Heart failure with reduced ejection fraction (HFrEF) has a well-established drug treatment with a wealth of supporting evidence from clinical trials. ACE inhibitors, or ARBs, beta blockers, and…

Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases, and even though understanding of the disease’s pathophysiology has…

Chronic heart failure (CHF) is a long-term condition primarily managed by angiotensin-converting enzyme (ACE) inhibitors, oral beta blockers, or oral diuretics. The addition of a second- or third-…

Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India,…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic heart failure (CHF) patient populations, covering 171…

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF…

Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…

Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers…

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved…

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…